期刊
ANTIBODIES
卷 11, 期 3, 页码 -出版社
MDPI
DOI: 10.3390/antib11030056
关键词
therapeutic antibodies; administration routes; drug delivery; clinical trials
类别
资金
- University of Tours
- French National Research Agency [ANR-10-LABX-53-01]
- Region Centre-Val de Loire (Novantinh program)
This review provides an overview of alternative routes of administration for delivering therapeutic antibodies, highlighting their physical and biological fundamentals, as well as their strengths and limitations. In addition to the commonly used intravenous (IV) route, topical delivery has shown clinical successes in improving drug bioavailability and efficacy while reducing side effects. Further research is needed to understand the impact of biological barriers on local delivery and optimize delivery methods and formulations for antibodies.
Background: For the past two decades, there has been a huge expansion in the development of therapeutic antibodies, with 6 to 10 novel entities approved each year. Around 70% of these Abs are delivered through IV injection, a mode of administration allowing rapid and systemic delivery of the drug. However, according to the evidence presented in the literature, beyond the reduction of invasiveness, a better efficacy can be achieved with local delivery. Consequently, efforts have been made toward the development of innovative methods of administration, and in the formulation and engineering of novel Abs to improve their therapeutic index. Objective: This review presents an overview of the routes of administration used to deliver Abs, different from the IV route, whether approved or in the clinical evaluation stage. We provide a description of the physical and biological fundamentals for each route of administration, highlighting their relevance with examples of clinically-relevant Abs, and discussing their strengths and limitations. Methods: We reviewed and analyzed the current literature, published as of the 1 April 2022 using MEDLINE and EMBASE databases, as well as the FDA and EMA websites. Ongoing trials were identified using clinicaltrials.gov . Publications and data were identified using a list of general keywords. Conclusions: Apart from the most commonly used IV route, topical delivery of Abs has shown clinical successes, improving drug bioavailability and efficacy while reducing side-effects. However, additional research is necessary to understand the consequences of biological barriers associated with local delivery for Ab partitioning, in order to optimize delivery methods and devices, and to adapt Ab formulation to local delivery. Novel modes of administration for Abs might in fine allow a better support to patients, especially in the context of chronic diseases, as well as a reduction of the treatment cost.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据